Clinical outcome of hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL): Experience from a single institution

Pathology and Oncology Research

Volumn 20, Issue 1, 2014, Pages 61-66

  Doki, Noriko ^a   Ohashi, Kazuteru ^a   Oshikawa, Gaku ^a   Kobayashi, Takeshi ^a   Kakihana, Kazuhiko ^a   Sakamaki, Hisashi ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Allogeneic hematopoietic stem cell transplantation (allo HSCT); Complete remission (CR); Tyrosine kinase inhibitor (TKI)

Indexed keywords

IMATINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORD BLOOD STEM CELL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HEALTH STATUS; HEMATOPOIETIC STEM CELL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; RETREATMENT; SEX DIFFERENCE; STEM CELL;

ADOLESCENT; ADULT; BENZAMIDES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84896030753     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-013-9658-5     Document Type: Article

References (17)

1. Gleissner B, Gokbuget N, Bartram CR et al (2002) Leading prognostic relevance of the BCR-ABLtranslocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Traial Group and confirmed polymerase chain reaction analysis. Blood 99:1536-1543 (Pubitemid 34533023)
2. Vinetti M, Fazi P, Cimino G et al (2007) Imatinib plus steroids induces complete remissons and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy:results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GI-MEMA) LAL0201-B protocol. Blood 109:3676-3678 (Pubitemid 46641715)
3. Lee S, Kim YJ, Min CK et al (2005) The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 105:3449-3457 (Pubitemid 40628185)
4. Lee HJ, Thompson JE, Wang ES et al (2011) Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer 117:1583-1594
5. Yanada M, Naoe T, Iida H et al (2005) Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. BMT 26:867-872 (Pubitemid 41655612)
6. Kebriaei P, Saliba R, Rondon G et al (2012) Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant 18:584-592
7. Fielding AK, Rowe JM, Richards SM et al (2009) Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG 2993. Blood 113:4489-4496
8. Mizuta S, Matsuo K, Yagasaki F et al (2011) Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia 25:41-47
9. Mizuta S, Matsuo K, Maeda T et al (2012) Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR-ABL-positive ALL. Blood Cancer J 2:e72
10. Spinelli O, Peruta B, Tosi M et al (2007) Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patints with high-risk acute lymphoblastic leukemia. Haematologica 92:612-618 (Pubitemid 350144263)
11. Burke MJ, Troz B, Baker KS et al (2009) Allo-hematopoietic cell transplantation for Ph chromosome-positive ALL: impact of imatinib on relapse and survival. BMT 43:107-113
12. Carpenter PA, Snyder DS, Flowers ME et al (2007) Prophilactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 109:2791-2793 (Pubitemid 46482072)
13. O'Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500-4505 (Pubitemid 40740783)
14. +) acute lymphoblastic leukemia. Blood 116:2070-2077
15. Foa R, Vitale A, Vifnwrri M et al (2011) Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 118:6521-6528
16. Caocci G, Vacca A, Ledda A et al (2012) Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Biol Blood Marrow Transplant 18:652-654
17. Teng CL, Yu JT, Chen HC, Hwang WL (2013) Maintenance therapy with dasatinib after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Hematol. doi:10.1007/s00277-012-1670-4